αMT

Closure of psx:substance/amt/section/history.full@1: 29 upstream, 18 downstream.

psx:substance/amt/section/history.full@1
├─ informed_by  claim/eaf33254-a000-4751-9707-ea3ebb024142  Claim in history — partially_supported
├─ informed_by  claim/36375afe-9233-478c-8704-c978a7e3d10b  Claim in history — partially_supported
├─ informed_by  claim/f2bf8b6a-1a74-4b53-94ff-663bf2cb019e  Claim in history — supported
├─ informed_by  claim/9c40d707-0f1a-41ff-9ef3-18600ccf8455  Claim in history — supported
├─ informed_by  claim/ac8931c2-9592-4ee5-b3f6-fe670440da4b  Claim in history — supported
  ├─ used  src/pmid:12678045  Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.
  ├─ used  src/pmid:15455477  Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
  ├─ used  src/doi:10.1007/s00204-015-1513-x  The hallucinogenic world of tryptamines: an updated review.
  ├─ used  src/doi:10.2174/1570159X13666141210222409
  ├─ used  src/pmid:16105268  Fatality due to acute alpha-methyltryptamine intoxication.
      ├─ used  src/url:20cb97e3473fcc7c  Alpha-methyltryptamine (Indopan) - NCATS Inxight Drugs
      ├─ used  src/doi:10.1016/j.toxlet.2017.03.007  In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks.
      ├─ used  src/doi:10.1016/j.neures.2025.04.006  A systematic study of changes in monoamine neurotransmitters in the rat brain following acute administration of alpha-methyltryptamine (AMT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT).
      ├─ used  src/doi:10.1097/FBP.0000000000000841
      ├─ used  src/doi:10.1016/j.expneurol.2021.113638  New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review.
      ├─ used  src/doi:10.1021/acschemneuro.2c00170  Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
      ├─ used  src/doi:10.1016/j.bbr.2018.07.020  5-Methoxy-alpha-methyltryptamine (5-MeO-AMT), a tryptamine derivative, induces head-twitch responses in mice through the activation of serotonin receptor 2a in the prefrontal cortex.
      ├─ used  src/url:3c1fc77ba0385127  AMT Drug Information - DrugWise
      ├─ used  src/url:c29bc5afd23f85d7  Legal Status of Alpha-methyltryptamine - Multiple Jurisdictions
      ├─ used  src/doi:10.1021/acschemneuro.5c00468  Dual Modulation of 5-HT2A Receptors and SERT by α-Ethyltryptamine and Its Optical Isomers.
      ├─ used  src/url:3ad72d5c592d8337  Release.org.uk - AMT Drug Information
      ├─ used  src/pmid:3091132  The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat.
      ├─ used  src/doi:10.1007/s00204-020-02693-7  Designer drugs: mechanism of action and adverse effects
      ├─ used  src/doi:10.3390/metabo13010092  Alpha-methyltryptamine (alpha-MT) Metabolite Profiling in Human Hepatocyte Incubations and Postmortem Urine and Blood
      ├─ used  src/doi:10.1007/s00213-021-05876-x  Serotonin toxicity of serotonergic psychedelics
      ├─ used  src/doi:10.1007/s00414-024-03236-w  Alpha-methyltryptamine and 5-(2-methylaminopropyl)-benzofuran (5-MAPB) fatal co-intoxication: case report and review of literature
      ├─ used  src/doi:10.3109/15563650.2014.885983  Patterns of presentation and clinical toxicity after reported use of alpha methyltryptamine in the United Kingdom. A report from the UK National Poisons Information Service.
      ├─ derived_from  gen/fa205cf9-0ea6-4773-8b45-a7f571ae0dd9  Generation — pipeline-v5
      └─ generated_by  pub/793ed85a-cf09-4c5b-a475-4376fad1f033  Publication — backfill
    ├─ used  version/1  Revision 1
    ├─ used  claim/669dac87-99c9-493c-a9db-7e384c9d1c5b  Claim in summary — supported
    ├─ used  claim/e31b36b3-bb42-4df1-aa5d-718175da24cd  Claim in clinical-evidence — partially_supported
    ├─ used  claim/6f730c06-7aab-4b75-8c4a-2ff1a68f8a3b  Claim in pharmacology — inconclusive  working
    ├─ used  claim/71340da0-c9b1-4bae-9944-fee7dbf42f21  Claim in comparative-pharmacology — inconclusive  working
    ├─ used  claim/8b517927-1153-45d9-a641-ca3b3c20f4c1  Claim in safety — supported
    ├─ used  claim/8b2c2b3d-014b-4697-a519-3d50f9cd3202  Claim in safety — inconclusive  working
      ├─ derived_from  issue/notice@76ddbaed5b37  Issued notice
      ├─ derived_from  issue/info_card@46bc1bb853c0  Issued info_card
      ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
      ├─ derived_from  issue/notice@a5727d1128c1  Issued notice
      ├─ derived_from  issue/info_card@edd9e6b4fbff  Issued info_card
      ├─ derived_from  issue/emergency@c15c760aabf6  Issued emergency
      ├─ informed_by  section/summary.full@1
      ├─ informed_by  section/clinical-evidence.full@1
      ├─ informed_by  section/pharmacology.full@1
      ├─ informed_by  section/comparative-pharmacology.full@1
      └─ informed_by  section/safety.full@1
… closure truncated at 200 nodes

indented by distance from this node, not by parentage